From Bench to Clinic: Advances in Anti‐Inflammatory Therapies for Atherosclerotic Coronary Artery Disease

ABSTRACT Atherosclerosis (AS) is a chronic, progressive inflammatory disorder characterized by the deposition of lipid‐laden plaques, infiltration of immune cells, and remodeling of vascular structures within arterial walls. It remains the primary pathological driver of atherosclerotic coronary artery disease (ASCAD) and a major contributor to global mortality. While conventional lipid‐lowering therapies, particularly statins, have significantly reduced the incidence of ASCAD by targeting hyperlipidemia, a considerable residual inflammatory risk continues to exist. This unresolved inflammation exacerbates plaque vulnerability, increases the likelihood of rupture, and precipitates thrombotic complications. Recent breakthroughs in understanding the complex inflammatory mechanisms underlying AS, including endothelial dysfunction, macrophage polarization, T‐cell activation, and the release of pro‐inflammatory cytokines, have revealed novel therapeutic targets. This mechanistic insight has spurred the development of innovative anti‐inflammatory strategies, including monoclonal antibodies targeting specific cytokines (e.g., IL‐1β, TNF‐α), epigenetic modulators, and immune‐based interventions. This review synthesizes the current understanding of the inflammatory pathogenesis of AS, evaluates the translational potential of emerging anti‐inflammatory therapies, and discusses the challenges in optimizing the balance between efficacy and safety. By bridging discoveries in basic science with clinical applicability, this analysis aims to guide future research and foster therapeutic innovations in combating ASCAD.